Full text

Turn on search term navigation

Copyright © 2023 Hanaa M. Sayed et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/

Abstract

Ethyl acetate fraction column chromatographic analysis was used to isolate eleven compounds (numerically tagged 1–10) from Cassia occidentalis L. in this study. Two unique metabolites, including a neolignan compound designated as occidentalignan I (9) and a flavonoidal glycoside, chrysin-7-O-α-L-rhamnopyranosyl (10), were identified, while silybin A (8) was the first flavonolignan to be isolated from the Fabaceae family. Four compounds, including β-sitosterol-3-O-β-D-glucopyranoside (1), stigmasterol-3-O-β-D-glucopyranoside (2), betulinic acid (3), and vanillic acid (4) were isolated from C. occidentalis for the first time. In addition, four known compounds, cinnamic acid (5), p-hydroxybenzoic acid (6), β- resorcylic acid (7), and citric acid (11), were also detected. The in-vitro cytotoxicity assessment of the methanolic extract of C. occidentalis on seven cancer cell lines, including A-549, Colo-205, Huh-7, HCT-116, PANC-1, SKOV-3, and BNL, demonstrated its selective potent cytotoxicity on lung cancer cells without affecting normal BNL cells. In contrast, the methanolic extract showed moderate activity on Colo-205 and Huh-7 and nearly no activity on HCT-116, PANC-1, and SKOV-3 cell lines. These results suggest that the methanolic extract of C. occidentalis is an excellent candidate with potential antiproliferative activity against lung cancer; however, further studies are necessary to clarify its mechanism of action.

Details

Title
Phytoconstituent Isolation and Cytotoxicity Evaluation of the Egyptian Cassia occidentalis L. Possessing Selective Activity against Lung Carcinoma
Author
Sayed, Hanaa M 1 ; Ramadan, Mahmoud A 1 ; Salem, Heba H 2 ; Fayed, Marwa A A 3   VIAFID ORCID Logo 

 Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt 
 Department of Pharmacognosy, Faculty of Pharmacy, Northern Border University, Rafha Region, Arar, Saudi Arabia 
 Department of Pharmacognosy, Faculty of Pharmacy, University of Sadat City, Sadat City 32897, Egypt 
Editor
Ashanul Haque
Publication year
2023
Publication date
2023
Publisher
John Wiley & Sons, Inc.
ISSN
20909063
e-ISSN
20909071
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2801794552
Copyright
Copyright © 2023 Hanaa M. Sayed et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/